Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback